CLSD · As filed with the SEC
Clearside Biomedical income statement, by quarter
The statement as Clearside Biomedical presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.
Consolidated Statements of Operations (unaudited) · USD, except per-share amounts
| USD, except per-share amounts | Q3 2025 3 months ended Sep 30, 2025 | Q2 2025 3 months ended Jun 30, 2025 | Q1 2025 3 months ended Mar 31, 2025 | Q4 2024† 3 months ended Dec 31, 2024 | Q3 2024 3 months ended Sep 30, 2024 | Q2 2024 3 months ended Jun 30, 2024 | Q1 2024 3 months ended Mar 31, 2024 | Q4 2023† 3 months ended Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|
| License and other revenue (includes $171 and $81 from a related party for the three months ended September 30, 2025 and 2024, respectively, and $655and $237 for the nine months ended September 30, 2025 and 2024, respectively) | 201,000 | 492,000 | 2,330,000 | — | 1,038,000 | 90,000 | 230,000 | — |
| Operating expenses: | ||||||||
| Cost of goods sold | 0 | 0 | 248,000 | — | 0 | 0 | — | — |
| Research and development (includes $255 and $473 to a related party for the three and nine months ended September 30, 2024, respectively) | 2,933,000 | 1,584,000 | 4,463,000 | — | 4,128,000 | 4,603,000 | 5,615,000 | — |
| General and administrative | 4,308,000 | 2,476,000 | 2,824,000 | — | 2,844,000 | 3,077,000 | 2,824,000 | — |
| Total operating expenses | — | — | — | — | — | — | 8,439,000 | — |
| Total operating expenses | 7,241,000 | 4,060,000 | 7,535,000 | — | 6,972,000 | 7,680,000 | — | — |
| Loss from operations | (7,040,000) | (3,568,000) | (5,205,000) | — | (5,934,000) | (7,590,000) | (8,209,000) | — |
| Interest income | 65,000 | 115,000 | 163,000 | — | 338,000 | 419,000 | 348,000 | — |
| Other expense | — | — | — | — | — | — | (1,499,000) | — |
| Other income (expense), net | — | — | — | 2,064,000† | 365,000 | 1,917,000 | — | 1,719,000† |
| Other income, net | 3,573,000 | 1,720,000 | 207,000 | — | — | — | — | — |
| Non-cash interest expense on liability related to the sales of future royalties | (2,570,000) | (2,762,000) | (2,673,000) | — | (2,457,000) | (2,340,000) | (2,403,000) | — |
| Loss before income taxes | (5,972,000) | (4,495,000) | (7,508,000) | — | — | — | — | — |
| Income tax expense | 0 | 0 | 715,000 | — | — | — | — | — |
| Net loss | (5,972,000) | (4,495,000) | (8,223,000) | — | (7,688,000) | (7,594,000) | (11,763,000) | — |
| Net loss per share of common stock - basic | (1.14) | (0.06) | (0.11) | — | (0.10) | (0.10) | (0.17) | — |
| Net loss per share of common stock - diluted | (1.14) | (0.06) | (0.11) | — | (0.10) | (0.10) | (0.17) | — |
| Weighted average shares outstanding - basic | 5,233,981 | 77,844,055 | 76,921,843 | — | 74,745,415 | 74,731,139 | 69,853,227 | — |
| Weighted average shares outstanding - diluted | 5,233,981 | 77,844,055 | 76,921,843 | — | 74,745,415 | 74,731,139 | 69,853,227 | — |
| Unrealized gain on available-for-sale investments | — | — | — | — | 6,000 | — | — | — |
| Unrealized gain on available-for-sale investments | 0 | 0 | — | — | — | (1,000) | — | — |
| Comprehensive loss | (5,972,000) | (4,495,000) | — | — | (7,682,000) | (7,595,000) | — | — |
† Derived: worked out from the filings, not stated in them. A fourth quarter is the 10-K year less the nine months in the third-quarter 10-Q; a quarter of cash flows is year to date less the prior year to date.
As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.